1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Alabama >
  6. Eurofins Discovery Acquires Discovery Biomed

M&A Deal Summary

Eurofins Discovery Acquires Discovery Biomed

On July 5, 2022, Eurofins Discovery acquired life science company Discovery Biomed

Acquisition Highlights
  • This is Eurofins Discovery’s 1st transaction in the Life Science sector.
  • This is Eurofins Discovery’s 1st transaction in the United States.
  • This is Eurofins Discovery’s 1st transaction in Alabama.

M&A Deal Summary
Date 2022-07-05
Target Discovery Biomed
Sector Life Science
Buyer(s) Eurofins Discovery
Deal Type Add-on Acquisition

Target

Discovery Biomed

Birmingham, Alabama, United States
Discovery Biomed is an operator of boutique biotechnology company seeks to contribute to improvements in human health through its expertise, work, and facilities by providing partners and clients with pilot screening and high-throughput screening (HTS) services for therapeutic-related bioassays, providing partners and clients with custom immortalized cell lines, and performing therapeutics discovery for certain failure-to-secrete diseases in humans. Discovery Biomed was founded in 2007 and is based in Birmingham, Alabama.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Eurofins Discovery

St Charles, Missouri, United States
Category Company
Sector Life Science
DESCRIPTION

Eurofins Discovery provides drug discovery researchers with the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling. Eurofins Discovery is based in St Charles, Missouri.

DEAL STATS #
Overall 1 of 2
Sector: Life Science M&A 1 of 2
Type: Add-on Acquisition M&A Deals 1 of 2
State: Alabama M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2022 M&A 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-04-25 Calixar

Lyon, France

Calixar discovers and develops new approaches to isolate full-length membrane therapeutic targets with the highest purity levels. The company develops its own pipeline of medically relevant targets and can also utilize its patented technology platform for other companies that need to identify, express, extract and purify membrane proteins (GPCRs, ion channels, receptors, transporters and viral targets). Calixar was founded in 2011 and is based in Lyon, France.

Buy -
Mergr

Solution for

Product

Company

Legal